Endo International PLC (ENDP) Receives $13.55 Average PT from Brokerages
Shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) have been assigned an average rating of “Hold” from the twenty-four research firms that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $12.37.
A number of brokerages have recently commented on ENDP. William Blair reiterated a “market perform” rating on shares of Endo International PLC in a research report on Wednesday, June 14th. Stifel Nicolaus cut Endo International PLC from a “buy” rating to a “hold” rating and decreased their price objective for the company from $22.00 to $15.00 in a report on Friday, June 9th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $9.00 price objective (down from $15.00) on shares of Endo International PLC in a research report on Wednesday, August 9th. Morgan Stanley decreased their price target on Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 10th. Finally, Deutsche Bank AG set a $13.00 price target on Endo International PLC and gave the stock a “buy” rating in a report on Wednesday, August 9th.
Shares of Endo International PLC (NASDAQ ENDP) traded up 6.13% during mid-day trading on Wednesday, reaching $9.09. 6,405,722 shares of the company’s stock were exchanged. Endo International PLC has a one year low of $7.41 and a one year high of $21.87. The company’s market capitalization is $2.03 billion. The company’s 50-day moving average price is $8.73 and its 200-day moving average price is $10.80.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.19. The company had revenue of $875.73 million during the quarter, compared to analysts’ expectations of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.86 earnings per share. On average, equities analysts expect that Endo International PLC will post $3.52 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Endo International PLC (ENDP) Receives $13.55 Average PT from Brokerages” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/endo-international-plc-endp-receives-13-55-average-pt-from-brokerages/1603879.html.
In other news, COO Terrance J. Coughlin acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were acquired at an average price of $7.70 per share, with a total value of $154,000.00. Following the acquisition, the chief operating officer now directly owns 181,369 shares in the company, valued at $1,396,541.30. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Paul Campanelli acquired 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was purchased at an average cost of $7.71 per share, for a total transaction of $50,115.00. Following the acquisition, the chief executive officer now owns 213,620 shares in the company, valued at $1,647,010.20. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 36,000 shares of company stock worth $279,460. 0.50% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the business. Piedmont Investment Advisors LLC increased its stake in shares of Endo International PLC by 43.4% in the second quarter. Piedmont Investment Advisors LLC now owns 59,211 shares of the company’s stock valued at $661,000 after purchasing an additional 17,928 shares during the period. Nomura Holdings Inc. acquired a new position in shares of Endo International PLC during the second quarter worth approximately $745,000. Flinton Capital Management LLC boosted its position in shares of Endo International PLC by 64.4% during the second quarter. Flinton Capital Management LLC now owns 20,400 shares of the company’s stock worth $228,000 after buying an additional 7,990 shares during the period. Bank of Hawaii acquired a new position in shares of Endo International PLC during the second quarter worth approximately $180,000. Finally, Parametric Portfolio Associates LLC boosted its position in shares of Endo International PLC by 18.7% during the second quarter. Parametric Portfolio Associates LLC now owns 398,099 shares of the company’s stock worth $4,447,000 after buying an additional 62,822 shares during the period. 90.71% of the stock is owned by hedge funds and other institutional investors.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.